Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: MythMan who wrote (187564)	8/13/2002 5:02:54 PM
From: yard_man	Read Replies (1) \| Respond to of 436258

>>Dreman is also a fan of some beleaguered drug stocks, including Merck (NYSE:MRK - News), Schering-Plough (NYSE:SGP - News), and Bristol-Myers Squibb (NYSE:BMY - News). He thinks investors are focusing too heavily on patent expirations and weak drug pipelines, which has left many blue-chip drugmakers undervalued. He points to Bristol-Myers, which trades at just 19 times projected 2003 earnings. Dreman says those projections assume the company won't produce any new drugs next year, which he considers an unlikely scenario. Another selling point is Bristol's healthy 4.8% dividend yield.<<